Discounted Cash Flow (DCF) Analysis Levered
Newron Pharmaceuticals SpA (NP5.DE)
3.54 €
0.00 (0.00%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 13.43 | 4.03 | 7.04 | 5.26 | 5.76 | 5.61 | 5.45 | 5.30 | 5.16 | 5.02 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -8.40 | -16.11 | -22.21 | -15.59 | -11.44 | -14.28 | -13.89 | -13.51 | -13.14 | -12.79 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.06 | -0.04 | -0.05 | -0.03 | -0.02 | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -8.47 | -16.15 | -22.26 | -15.62 | -11.47 | -14.31 | -13.92 | -13.54 | -13.18 | -12.82 |
Weighted Average Cost Of Capital
| Share price | $ 3.54 |
|---|---|
| Beta | 2.153 |
| Diluted Shares Outstanding | 17.84 |
| Cost of Debt | |
| Tax Rate | -0.11 |
| After-tax Cost of Debt | 6.77% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 13.795 |
| Total Debt | 43.08 |
| Total Equity | 63.17 |
| Total Capital | 106.25 |
| Debt Weighting | 40.55 |
| Equity Weighting | 59.45 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 13.43 | 4.03 | 7.04 | 5.26 | 5.76 | 5.61 | 5.45 | 5.30 | 5.16 | 5.02 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.40 | -16.11 | -22.21 | -15.59 | -11.44 | -14.28 | -13.89 | -13.51 | -13.14 | -12.79 |
| Capital Expenditure | -0.06 | -0.04 | -0.05 | -0.03 | -0.02 | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 |
| Free Cash Flow | -8.47 | -16.15 | -22.26 | -15.62 | -11.47 | -14.31 | -13.92 | -13.54 | -13.18 | -12.82 |
| WACC | ||||||||||
| PV LFCF | -12.90 | -11.31 | -9.92 | -8.70 | -7.62 | |||||
| SUM PV LFCF | -50.45 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 10.95 |
| Free cash flow (t + 1) | -13.07 |
| Terminal Value | -146.08 |
| Present Value of Terminal Value | -86.89 |
Intrinsic Value
| Enterprise Value | -137.34 |
|---|---|
| Net Debt | 18.06 |
| Equity Value | -155.40 |
| Shares Outstanding | 17.84 |
| Equity Value Per Share | -8.71 |